Delivery Order SPE2DB20D2104-SPE2DB22FS77T

Award Date 5/18/22
Potential Completion Date 5/19/22
Potential Value $10K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order valued at $2,352.00 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as...
This federal contract award is for a delivery order to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The award, valued at $1,080.48, was made by the Defense Logistics Agency (DLA) under an Indefinite Delivery Contract (IDC) with the company worth up to $999,999,999.00. This IDC, which runs through November 2026, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and...
This federal contract award, valued at $1,080.48, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RESTASIS 0.05% eye emulsion. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on January 3, 2022. The contract, valued at $9,109.98, is for the delivery of RESTASIS 0.05% eye emulsion. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999 and running through November 2026. The IDC serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $38,052.66 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract has an ultimate completion date of June 30, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $50,726.84, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription eye medication, to support federal healthcare programs. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which...
This federal contract award, valued at $3,020.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a delivery order, is for the supply of Restasis 0.05% eye emulsion. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC...
This federal contract award, valued at $2,745.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a Firm Fixed Price Delivery Order for the supply of RESTASIS 0.05% Eye Emulsion 30s, a prescription eye medication. The contract has an ultimate completion date of May 28, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,424.90, is a delivery order for the supply of RESTASIS 0.05% eye emulsion. The contract has an ultimate completion date of December 6, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $75,226.89, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of pharmaceutical...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB22FS77T
    Delivery Order

This federal contract award, valued at $10,247.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of RESTASIS 0.05% eye emulsion, a prescription medication, with a completion date of May 19, 2022. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2025. The IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This award did not have a set-aside designation, indicating open competition. Amerisourcebergen's extensive experience in pharmaceutical distribution and its ability to efficiently fulfill government contracts for essential medical commodities make it a key supplier to the Department of Defense and other federal agencies.

Generated 2/27/25, 10:51 AM